James Oates is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2125 Charlie Hall Blvd
Charleston, SC 294145879
Telephone
843-573-1500Provider last certified this registry record 20 Oct 2020.
Clinical trials
- Vitamin D to Improve Endothelial Function in SLE
Sponsor: Medical University of South Carolina
- Balancing Lupus Experiences With Stress Strategies
Sponsor: Medical University of South Carolina
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20254 payments
- ABBVIE INC.Program year20241 payment
- E.R. Squibb & Sons, L.L.C.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
31.1%TNF inhibitor13.3%Humira Pen33%Humira(Cf) Pen31%Enbrel Sureclick24%Humira(Cf)11%Part D<11 patientsFolate Analog Metabolic Inhibitor8.9%Methotrexate89%Otrexup11%Part D<11 patients+ 5 more classes in this area
Nervous system
27.3%Opioid Agonist11.5%Tramadol Hcl69%Oxycodone Hcl21%Oxycodone-Acetaminophen11%Part D<11 patientsGabapentinoids9%Gabapentin52%Pregabalin48%Part D≥15 patients+ 5 more classes in this area
Metabolism & gastrointestinal
15.9%Corticosteroid10.3%Prednisone100%Part D≥50 patientsAminosalicylate2.5%Sulfasalazine100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 1998–2025 per NIH RePORTER. The latest:
- Improving Health in Rheumatic Diseases (ImHeaRD)
Medical University of South Carolina
FY2025$659,475P30AR072582 - Improving Health in Rheumatic Disease (IMHeaRD)
Medical University of South Carolina
FY2025$219,825P30AR072582 - Improving Health in Rheumatic Disease (IMHeaRD)
Medical University of South Carolina
FY2025$219,825P30AR072582
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”